Allogene Therapeutics, Inc. (ALLO) Operating cash flow 2018–2025
Allogene Therapeutics, Inc. (ALLO) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$149.2MFY2025 · since FY2018: -$44.7M → -$149.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$149.2M | +25.5% |
| FY2024 | -$200.3M | +15.7% |
| FY2023 | -$237.7M | -7.8% |
| FY2022 | -$220.5M | -19.3% |
| FY2021 | -$184.8M | -60.6% |
| FY2020 | -$115.1M | +16.2% |
| FY2019 | -$137.3M | -207.6% |
| FY2018 | -$44.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice